OCA
KRON

Octagon Capital Advisors’s Kronos Bio KRON Stock Holding History

Octagon Capital Advisors’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-146,173
Closed -$3.5M – 31
2021
Q2 		$3.5M Hold
146,173
– – 0.73% 32
2021
Q1 		$4.28M Hold
146,173
– – 1.61% 21
2020
Q4 		$4.37M Buy
+146,173
New +$4.59M 1.51% 23

Other funds holding KRON

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Octagon Capital Advisors's KRON Position: Q3 2021 in Review

Octagon Capital Advisors sold out of Kronos Bio (KRON) in Q3 2021, closing a stake of 146,173 shares — an estimated $3.5M sold.

Octagon Capital Advisors first reported a position in KRON in Q4 2020 and held it in 3 quarters. The position peaked at $4.37M in Q4 2020. 83 funds tracked by Wall St. Rank hold KRON as of Q3 2021.

  • Octagon Capital Advisors reported no remaining Kronos Bio position as of Q3 2021 after selling out during the quarter.
  • Octagon Capital Advisors sold 146,173 Kronos Bio shares in Q3 2021, an estimated $3.5M.
  • Octagon Capital Advisors first reported a position in Kronos Bio in Q4 2020 and held it in 3 quarters.
  • Octagon Capital Advisors's Kronos Bio position peaked at $4.37M in Q4 2020.
  • 83 funds tracked by Wall St. Rank held Kronos Bio as of Q3 2021.

Based on Octagon Capital Advisors's 13F filing for Q3 2021, filed 15 Nov 2021.